Durham, United States
StrideBio, Inc, founded in 2015, is a pioneering gene therapy company headquartered in the United States. Their slogan, "The next evolution in gene therapy," underscores their commitment to developing transformative genetic medicines. StrideBio's innovative approach addresses the challenges of first-generation gene therapies through their proprietary structure-inspired adeno-associated virus (AAV) vector engineering platform.
This platform allows them to create unique AAV vectors with enhanced characteristics, such as evasion of pre-existing neutralizing antibodies, improved tissue targeting, and scalability in manufacturing. These improvements aim to bring life-changing treatments for patients with devastating conditions, especially in the realm of monogenic rare diseases.
Their strategic capabilities are further strengthened by a 24,000-square-foot facility in Research Triangle Park, N.C., encompassing offices, research labs, and in-housing manufacturing. The company received its latest investment via acquisition by Ginkgo Bioworks on April 1, 2023.
